Agios Pharmaceuticals Inc (NASDAQ:AGIO) was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating in a research note issued on Friday.

Other analysts have also issued research reports about the company. Oppenheimer Holdings, Inc. restated an “outperform” rating and issued a $83.00 price objective (up previously from $75.00) on shares of Agios Pharmaceuticals in a research note on Thursday, August 10th. SunTrust Banks, Inc. reiterated a “buy” rating and set a $80.00 target price (up previously from $68.00) on shares of Agios Pharmaceuticals in a research note on Tuesday, August 8th. Cann reiterated a “buy” rating and set a $75.00 target price on shares of Agios Pharmaceuticals in a research note on Sunday, June 11th. Leerink Swann upgraded Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $50.00 to $80.00 in a research note on Wednesday, August 2nd. Finally, Janney Montgomery Scott reiterated a “hold” rating on shares of Agios Pharmaceuticals in a research note on Tuesday, August 1st. Four research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Agios Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $74.75.

Agios Pharmaceuticals (NASDAQ:AGIO) traded down 2.70% during mid-day trading on Friday, reaching $61.55. The company’s stock had a trading volume of 440,992 shares. The company has a 50 day moving average of $58.43 and a 200-day moving average of $53.46. The stock’s market cap is $2.98 billion. Agios Pharmaceuticals has a 52-week low of $36.49 and a 52-week high of $67.74.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.57) by $0.21. The business had revenue of $11.30 million during the quarter, compared to the consensus estimate of $10.68 million. Agios Pharmaceuticals had a negative net margin of 732.26% and a negative return on equity of 81.64%. Agios Pharmaceuticals’s quarterly revenue was up 62.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.47) EPS. Equities analysts forecast that Agios Pharmaceuticals will post ($7.07) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Agios Pharmaceuticals Inc (AGIO) Lifted to “Hold” at ValuEngine” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/01/agios-pharmaceuticals-inc-agio-lifted-to-hold-at-valuengine.html.

In related news, Director Lewis Clayton Jr. Cantley sold 4,000 shares of the stock in a transaction that occurred on Wednesday, August 23rd. The stock was sold at an average price of $56.85, for a total transaction of $227,400.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO David P. Schenkein sold 3,000 shares of the stock in a transaction that occurred on Wednesday, June 7th. The stock was sold at an average price of $50.02, for a total value of $150,060.00. Following the sale, the chief executive officer now directly owns 1,100 shares in the company, valued at approximately $55,022. The disclosure for this sale can be found here. Insiders have sold 81,084 shares of company stock worth $4,688,712 in the last three months. 10.55% of the stock is currently owned by company insiders.

Large investors have recently modified their holdings of the company. Bank of Montreal Can increased its stake in shares of Agios Pharmaceuticals by 11.7% in the first quarter. Bank of Montreal Can now owns 2,068 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 216 shares in the last quarter. Blue Sky Asset Management LLC bought a new stake in shares of Agios Pharmaceuticals during the first quarter worth about $129,000. Russell Investments Group Ltd. increased its stake in shares of Agios Pharmaceuticals by 163.9% in the first quarter. Russell Investments Group Ltd. now owns 2,549 shares of the biopharmaceutical company’s stock worth $149,000 after buying an additional 1,583 shares in the last quarter. QS Investors LLC bought a new stake in shares of Agios Pharmaceuticals during the second quarter worth about $144,000. Finally, Advantage Investment Management LLC increased its stake in shares of Agios Pharmaceuticals by 109.7% in the first quarter. Advantage Investment Management LLC now owns 3,250 shares of the biopharmaceutical company’s stock worth $190,000 after buying an additional 1,700 shares in the last quarter. 94.30% of the stock is currently owned by institutional investors and hedge funds.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Stock Ratings for Agios Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.